Royalty Report: Drugs, Delivery – Collection: 245882


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 245882

License Grant
With this amendment, the French Licensor desires to amend the list of patent applications and patents encompassed within Licensors Patents Rights with the Licensee of Ireland.
License Property
Patents are added for Medicinal and/or nutritional microcapsules for oral administration, and,  Galenic microparticulate oral formulation for delayed and controlled release of pharmaceutical active principles.  This agreement also includes a list of deleted patents.
Field of Use
Per the original agreement, the Micropump® technology is a controlled release and taste-masking technology for the oral administration of small molecule drugs.

IPSCIO Record ID: 338651

License Grant
Licensor of Ireland grants the Licensee, also of Ireland, an exclusive, sublicensable license, solely in the field in the territory to use the Licensor technology, including intellectual property rights to sell and market and exploit the regulatory filings for the products in the field in the territory
License Property
LiquiTime® is a drug delivery platform for modified, extended and controlled release of liquid oral drugs.

Licensor has technology called Liquitime that may be used for developing modified/controlled release oral pharmaceutical products in a liquid suspension formulation.

The patent is titled Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s).

Field of Use
Licensee has licensed rights to the LiquiTime® drug delivery platform for the U.S. Over-the-Counter (OTC) drug market.

The exclusive license includes Licensor’s LiquiTime® Ibuprofen and LiquiTime® Guaifenesin oral suspensions; ibuprofen, an anti-inflammatory and Guaifenesin, an expectorant.  These are the initial products.

IPSCIO Record ID: 245879

License Grant
The French Licensor grants to the Licensee in Puerto Rico, an exclusive license, even as to Licensor, with the right to grant sublicenses, under Licensed Technology, to make, have made, use, sell, offer for sale The Parties  have undertaken a feasibility study to develop a Formulation by applying the Licensors Micropump Technology to Carvedilol.
License Property
Licensor has developed certain proprietary technology related to Licensor Micropump Technology.

Carvedilol11 means (l-(9H-carbazol-4-yloxy)-[[2-2(2-methoxyphenoxy)ethyl] amino ]-2-propanol), the compound that is known by the generic name of Carvedilol and including all racemates, chelates, complexes, enantiomers, diastereoisomers, salts, bases, esters, hydrates, solvates, polymorphs, crystal forms, crystal habits, prodrugs, isotopic or radiolabeled equivalents, metabolites, or the like, thereof and all mixtures and any of the foregoing, and compositions comprising Carvedilol.

Licensor Micropump Technology means a multiple-dose system containing a large number of microparticles that may be contained in capsule, tablet, orally dispersible, sachet or suspension formulations. It is expected that the microparticles are released in the stomach and pass into the small intestine, where each microparticle operates as a miniature delivery system, releasing the drug at a controlled rate and over an extended period of time.

Licensor Patent Rights means all patents and patent applications in existence as of the Effective Date or during the Term of this Agreement claiming generically or specifically a product or process using the Licensors Micropump Technology.

Product means any presentation or presentations of Carvedilol that incorporate the Licensed Technology, alone or in combination with other therapeutically active compounds, for the therapeutic or prophylactic treatment of diseases and conditions in humans in any dosage or strength.

Field of Use
The Micropump® technology is a controlled release and taste-masking technology for the oral administration of small molecule drugs.

IPSCIO Record ID: 243442

License Grant
Assignor sells, transfers, assigns and delivers to Assignee all of Assignors right, title and interest in and to the Patent Application and the Intellectual Property.
License Property
The Licensors technology is known as oral extended release dosage form based on the principle of controlled hydration.

The CDT system is used in solid oral dosage forms, the preferred route for drug administration. This technology is designed to produce tablets or capsules that release their active agents predictably and programmably over a specified timeframe of up to 24 hours. We believe we can apply our technology to create significant enhancements to existing pharmaceutical, OTC and nutraceutical products.

Proprietary CDT technology improves upon conventional multiple daily dose immediate release forms of existing products by providing the therapeutic benefits of controlled release drug delivery. In addition, we believe our technology can provide enhanced dosage formats for existing medications that provide superior patient convenience and product differentiation.

Field of Use
The use is for oral extended release dosage.

The technology has allowed Assignor cost-effectively develop formulations for the OTC and nutritional industries, such as  glucosamine, glucosamine/chondroitin, niacin, pseudoephedrine, caffeine, vitamin C, Novasoy®, and other difficult compounds and branded ingredients.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.